Immunotherapy Archives

News and Trends 6 Jul 2015

Kiadis launches its Cell-based Immunotherapies on European stock markets

Kiadis Pharma has launched an IPO on Euronext Amsterdam and Euronext Brussels with the aim of raising €32.7M. The company will invest the money in two cell-based immunotherapies for blood cancer and inherited blood disorders. Kiadis has filed for an Initial Public Offering on the Dutch and Belgian exchange markets. The money raised on the […]

July 6, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 Jul 2015

Lilly Cooperates with Immunocore to Fight Skin Cancer

Eli Lilly expands its portfolio in immune-oncology therapies. This time, Immunocore‘s lead T cell receptor-based drug, IMCgp100 is tested in combination with Lilly’s kinase inhibitors galunisertib and merestinib. This second collaboration between these two companies aims to increase drug efficacy against melanoma cancer. Melanomas are rare forms of skin cancer, that have a high potential […]

July 3, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 25 Jun 2015

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Personalized medicine is the next thing and immunotherapy expert BioNTech is determined to build its place in this competitive field. With this purpose in mind, the German biotech will partner with Siemens to build a new production plant for personalized cancer vaccines. Founded in 2008, the BioNTech Group has become one of the fastest-growing biotechnology […]

June 25, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 22 Jun 2015

Medigene plans to fund its T-cell program with €50 Millions

Munich-based Medigene is planning to raise cash through existing shareholders’ investments. The company targets up to €50M to propel its immune-oncology program with T-Cell Receptors and Dendritic Cells vaccines assets. Medigene plans a cash capital increase with subscription rights for existing shareholders by offering a new batch of shares. The company is going to present […]

June 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 19 Jun 2015

Celyad, the new face of Cardio3, is launching an IPO on NASDAQ

[UPDATE 19/06/2015]: Yesterday, Celyad launched its IPO on NASDAQ and the closing is expected to occur on 24 June 2015. Celyad, formely known as Cardio3, is preparing to cross the Atlantic to launch an IPO on NASDAQ. The company, which is already listed on Euronext Paris and Euronext Brussels, aims to raise €103.2M ($115 million) on […]

June 19, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 Jun 2015

Polaris, a new Nordic leader in Immuno-Oncology

Immuno-oncology is a busy market to take on by yourself due to the existing fierce competition. Targovax and Oncos Therapeutics have decided to merge to earn a spot in the field. Polaris, the combined business, contemplates a private placement of around €15M to fund the freshly baked company. Finland and Norway never were this close as Oncos […]

June 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Jun 2015

Pieris Pharma: is it worth going to NASDAQ for only €31 Million?

Pieris Pharmaceutical is planning to raise €31M in an surprisingly low US IPO. The company seeks to advance its early-stage pipeline with a special focus on its anemia treatment, Pieris’s most advanced candidate which recently completed the enrollment of its Phase I. Pieris’ pipeline might be premature, but it is ambitious. The company’s focus includes […]

June 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Jun 2015

[Update] AstraZeneca to buy a CAR-T expert?

[Update] Bloomberg announced that they make wrong conclusions from their discussion with AstraZeneca’s CEO Pascal Soriot. The CEO was not talking about the specific acquisition of Juno Therapeutics but about a potential acquisition of a CAR-T expert. Juno’s shares rose as much as 15.8 % just after the rumor was released by Bloomerg. Here is the first version […]

June 4, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 2 Jun 2015

Immuno-oncology race gets bloodier: BMS is suing its former executive now working for AstraZeneca

Immuno-oncology has gone from a competition to a battlefield. Bristol-Meyer Squibb launched a lawsuit against David Berman, a former researcher that abruptly quit last month after 10 years working for the company’s cancer R&D division. Berman, with his deep knowledge about BMS’s immune-oncology research, headed to AstraZeneca, BMS’ principal opponent. Game on. In this competitive […]

June 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 29 May 2015

Pfizer to Control Cellectis in a €1.5 Billion Deal?

Rumors are saying that French Cellectis is in talks about its potential sale. US-giant Pfizer is considered to be among the buyers. According to The Financial Time, two people familiar with the situation said Cellectis was in negotiations over a deal, but warned no outcome was certain. The Financial Time also declared that “one person […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 19 May 2015

PsiOxus raised €34.7 Million from First-Class investors

PsiOxus Therapeutics has closed a Series C financing round of €34.7M (£25 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes. Neil Woodford’s fund, GlaxoSmithKline’s VC unit and Imperial Innovations from Imperial College of London, amongst others, are behind the financing. PsiOxus’ lead product, enadenotucirev, is an oncolytic virus that, […]

May 19, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 May 2015

European Union supports Bavarian Nordic to cure Ebola

Bavarian Nordic has been granted €50M loan from the European Investment Bank (EIB) to support the companies’ pipeline including novel vaccines against Ebola and other infectious diseases as well as cancer immunotherapies. The loan is a three-to-five year bullet loan with fixed or variable interest payment. Bavarian Nordic has up to 18 months to draw […]

May 15, 2015 - 2 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Kiadis launches its Cell-based Immunotherapies on European stock markets

Lilly Cooperates with Immunocore to Fight Skin Cancer

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Medigene plans to fund its T-cell program with €50 Millions

Celyad, the new face of Cardio3, is launching an IPO on NASDAQ

Polaris, a new Nordic leader in Immuno-Oncology

Pieris Pharma: is it worth going to NASDAQ for only €31 Million?

[Update] AstraZeneca to buy a CAR-T expert?

Immuno-oncology race gets bloodier: BMS is suing its former executive now working for AstraZeneca

Pfizer to Control Cellectis in a €1.5 Billion Deal?

PsiOxus raised €34.7 Million from First-Class investors

European Union supports Bavarian Nordic to cure Ebola

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!